ES2341013T3 - Metodo para la medicion cuantitativa y/o comparativa de niveles de expresion de mrna en muestras biologicas pequeños. - Google Patents
Metodo para la medicion cuantitativa y/o comparativa de niveles de expresion de mrna en muestras biologicas pequeños. Download PDFInfo
- Publication number
- ES2341013T3 ES2341013T3 ES05744405T ES05744405T ES2341013T3 ES 2341013 T3 ES2341013 T3 ES 2341013T3 ES 05744405 T ES05744405 T ES 05744405T ES 05744405 T ES05744405 T ES 05744405T ES 2341013 T3 ES2341013 T3 ES 2341013T3
- Authority
- ES
- Spain
- Prior art keywords
- multiplication
- dna
- sequence
- cdna
- primers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 230000000052 comparative effect Effects 0.000 title claims abstract description 7
- 238000005259 measurement Methods 0.000 title claims description 22
- 230000014509 gene expression Effects 0.000 title description 30
- 239000012472 biological sample Substances 0.000 title 1
- 239000002299 complementary DNA Substances 0.000 claims abstract description 117
- 238000006243 chemical reaction Methods 0.000 claims abstract description 102
- 238000010839 reverse transcription Methods 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 39
- 108020004414 DNA Proteins 0.000 claims description 148
- 239000000523 sample Substances 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 238000012986 modification Methods 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 239000003607 modifier Substances 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 230000007515 enzymatic degradation Effects 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 108060002716 Exonuclease Proteins 0.000 claims description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 102000013165 exonuclease Human genes 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000007834 ligase chain reaction Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 238000012175 pyrosequencing Methods 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 description 34
- 102000018690 Trypsinogen Human genes 0.000 description 29
- 108010027252 Trypsinogen Proteins 0.000 description 29
- 238000012163 sequencing technique Methods 0.000 description 21
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 19
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 19
- 239000000872 buffer Substances 0.000 description 14
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 13
- 102100029075 Exonuclease 1 Human genes 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 8
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 8
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- JZLLRGCJEXHGNF-UHFFFAOYSA-M potassium;2-aminoacetic acid;hydroxide Chemical compound [OH-].[K+].NCC(O)=O JZLLRGCJEXHGNF-UHFFFAOYSA-M 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- -1 pH 8.8 Chemical compound 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20040723A FI20040723A0 (fi) | 2004-05-26 | 2004-05-26 | Menetelmä mRNA:n ilmentymistasojen kvantitatiiviseksi ja/tai suhteelliseksi mittaamiseksi pienissä biologisissa näytteissä |
| FI20040723 | 2004-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2341013T3 true ES2341013T3 (es) | 2010-06-14 |
Family
ID=32338424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05744405T Expired - Lifetime ES2341013T3 (es) | 2004-05-26 | 2005-05-25 | Metodo para la medicion cuantitativa y/o comparativa de niveles de expresion de mrna en muestras biologicas pequeños. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7838228B2 (enExample) |
| EP (1) | EP1749105B1 (enExample) |
| JP (1) | JP5258289B2 (enExample) |
| AT (1) | ATE457361T1 (enExample) |
| AU (1) | AU2005248091B2 (enExample) |
| CA (1) | CA2568537C (enExample) |
| DE (1) | DE602005019285D1 (enExample) |
| DK (1) | DK1749105T3 (enExample) |
| ES (1) | ES2341013T3 (enExample) |
| FI (1) | FI20040723A0 (enExample) |
| WO (1) | WO2005116248A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
| EP2749654A1 (en) * | 2012-12-28 | 2014-07-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method of analysis of composition of nucleic acid mixtures |
| WO2017091809A1 (en) * | 2015-11-25 | 2017-06-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US11702702B2 (en) * | 2016-04-15 | 2023-07-18 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
| CN111394455A (zh) * | 2020-03-09 | 2020-07-10 | 皖南医学院 | 一种检测前列腺癌的试剂盒及其制备方法 |
| CN116606867B (zh) * | 2023-04-28 | 2024-01-26 | 北京启辰生生物科技有限公司 | 一种提高新冠全长S蛋白mRNA完整性的制备方法及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674679A (en) * | 1991-09-27 | 1997-10-07 | Amersham Life Science, Inc. | DNA cycle sequencing |
| US6258543B1 (en) | 1996-05-02 | 2001-07-10 | Xtrana, Inc. | Quantitation of RNA transcripts using genomic DNA as the internal amplification competitor |
| JPH1057064A (ja) | 1996-08-16 | 1998-03-03 | Rikagaku Kenkyusho | 微量遺伝子産物の特異的増幅方法 |
| WO1998035058A2 (en) | 1997-02-07 | 1998-08-13 | Ribozyme Pharmaceuticals, Inc. | Improved process for detection and quantification of nucleic acid molecules |
| US20030235884A1 (en) | 1999-06-15 | 2003-12-25 | Cummings Richard D. | Polynucleotides encoding core 1 beta3-galactosyl transferase and methods of use thereof |
| AU5830400A (en) | 1999-06-30 | 2001-01-22 | Arto Orpana | Diagnostic method for squamous cell carcinoma |
| JP2001078768A (ja) | 1999-09-16 | 2001-03-27 | Otsuka Pharmaceut Co Ltd | 遺伝子発現の測定法 |
| EP1257664A4 (en) * | 2000-01-28 | 2006-04-05 | Althea Technologies Inc | METHOD FOR THE ANALYSIS OF GENE EXPRESSION |
| KR20020089746A (ko) | 2001-05-24 | 2002-11-30 | 주식회사 커벡스 | 크기변형유도 앵커 시발체, 이를 이용한 알티-피씨알 방법및 이를 이용한 진단 방법 |
| US20040091857A1 (en) | 2001-07-20 | 2004-05-13 | Nallur Girish N. | Gene expression profiling |
| US20030022175A1 (en) | 2001-07-26 | 2003-01-30 | Harn-Jing Terng | Diagnostic assay of genetic mutations by discriminating amplification and hybridization |
| JP2004000039A (ja) * | 2002-05-30 | 2004-01-08 | Inst Of Physical & Chemical Res | 遺伝子多型の検出方法 |
| DE10224200C1 (de) * | 2002-05-31 | 2003-08-21 | Artus Ges Fuer Molekularbiolog | Vermehrung von Ribonukleinsäuren |
| JP2004113136A (ja) * | 2002-09-26 | 2004-04-15 | Yamaguchi Technology Licensing Organization Ltd | 非乳頭状腎細胞がんの感受性と相関するｍｍｐ−１プロモーターのｓｎｐを用いた腎細胞がんの発症リスクを予測する分子レベルでの検査方法 |
| JP2004135509A (ja) * | 2002-10-15 | 2004-05-13 | Hitachi Ltd | 遺伝子発現解析法及び遺伝子発現解析用プローブキット |
| WO2005110596A2 (en) | 2004-05-10 | 2005-11-24 | Gorilla Genomics, Inc. | Methods of quantifying targets in multiple samples |
-
2004
- 2004-05-26 FI FI20040723A patent/FI20040723A0/fi not_active Application Discontinuation
-
2005
- 2005-05-25 CA CA2568537A patent/CA2568537C/en not_active Expired - Fee Related
- 2005-05-25 EP EP05744405A patent/EP1749105B1/en not_active Expired - Lifetime
- 2005-05-25 ES ES05744405T patent/ES2341013T3/es not_active Expired - Lifetime
- 2005-05-25 JP JP2007513986A patent/JP5258289B2/ja not_active Expired - Lifetime
- 2005-05-25 US US11/596,543 patent/US7838228B2/en not_active Expired - Fee Related
- 2005-05-25 DE DE602005019285T patent/DE602005019285D1/de not_active Expired - Lifetime
- 2005-05-25 DK DK05744405.1T patent/DK1749105T3/da active
- 2005-05-25 WO PCT/FI2005/050176 patent/WO2005116248A1/en not_active Ceased
- 2005-05-25 AU AU2005248091A patent/AU2005248091B2/en not_active Ceased
- 2005-05-25 AT AT05744405T patent/ATE457361T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005019285D1 (de) | 2010-03-25 |
| AU2005248091B2 (en) | 2009-12-17 |
| EP1749105B1 (en) | 2010-02-10 |
| JP5258289B2 (ja) | 2013-08-07 |
| WO2005116248A1 (en) | 2005-12-08 |
| US7838228B2 (en) | 2010-11-23 |
| AU2005248091A1 (en) | 2005-12-08 |
| CA2568537C (en) | 2013-04-02 |
| FI20040723A0 (fi) | 2004-05-26 |
| DK1749105T3 (da) | 2010-05-25 |
| US20080286769A1 (en) | 2008-11-20 |
| CA2568537A1 (en) | 2005-12-08 |
| JP2008500034A (ja) | 2008-01-10 |
| ATE457361T1 (de) | 2010-02-15 |
| EP1749105A1 (en) | 2007-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jakupciak et al. | Mitochondrial DNA as a cancer biomarker | |
| US9228239B2 (en) | High resolution melting analysis as a prescreening tool | |
| JP2018530347A (ja) | インサイチュ増幅により無細胞核酸分子を調製する方法 | |
| JP2007525998A (ja) | 脆弱ｘ症候群などのｓｔｒｐの検出 | |
| Du et al. | Terminal deoxynucleotidyl transferase-activated nicking enzyme amplification reaction for specific and sensitive detection of DNA methyltransferase and polynucleotide kinase | |
| CN105793438B (zh) | 未知序列的双股线性核酸的全长扩增方法 | |
| ES2705573T3 (es) | Procedimientos y composiciones para detectar mutaciones en el gen EZH2 humano | |
| CN108251510A (zh) | 一种叶酸代谢能力基因分型的试剂盒、检测方法及其应用 | |
| Kirches | MtDNA as a cancer marker: a finally closed chapter? | |
| ES2341013T3 (es) | Metodo para la medicion cuantitativa y/o comparativa de niveles de expresion de mrna en muestras biologicas pequeños. | |
| CN102229989A (zh) | 一种结核分枝杆菌乙胺丁醇耐药突变的检测方法及试剂盒 | |
| CN103074438A (zh) | 一种指导华法林用药的多重基因检测试剂盒及其检测方法 | |
| CN114667355B (zh) | 检测结直肠癌的方法 | |
| CN106755330B (zh) | 癌症相关基因表达差异检测试剂盒及其应用 | |
| Bhat et al. | DNA methylation detection at single base resolution using targeted next generation bisulfite sequencing and cross validation using capillary sequencing | |
| CN107287309A (zh) | 一种血液循环肿瘤dna点突变检测方法 | |
| KR20210147348A (ko) | 알츠하이머 질환의 진단을 위한 Ｅｅｆ１ａ１의 용도 | |
| CN107058608A (zh) | 用于检测dpyd*2a遗传多态性的引物、探针及检测试剂盒 | |
| JP6551656B2 (ja) | 卵巣癌に関する情報の取得方法、ならびに卵巣癌に関する情報を取得するためのマーカーおよび卵巣癌検出用キット | |
| CN117363729A (zh) | 用于体外检测肝癌的试剂盒及其应用 | |
| CN100460520C (zh) | 采用碱基序列测定法比较同一基因在不同来源中的表达量的方法 | |
| JP2016192909A (ja) | 胃癌に関する情報の取得方法、ならびに胃癌に関する情報を取得するためのマーカーおよび胃癌検出用キット | |
| CN117716049A (zh) | 用多阻断探针通过阻断置换扩增的微卫星基因座高灵敏度检测及其在微卫星不稳定性检测中的用途 | |
| CN112301096A (zh) | 一种新型核酸探针标记方法 | |
| CN113913514A (zh) | 人ctnnb1基因突变的数字pcr检测方法及应用 |